Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.
The benzothiophene LY329146 reverses the drug resistance phenotype in multidrug resistance protein (MRP1)-overexpressing cells when dosed in combination with MRP1-associated oncolytics doxorubicin and vincristine. Additionally, LY329146 inhibited MRP1-mediated uptake of the MRP1 substrate LTC4 into membrane vesicles prepared from MRP1-overexpressing cells.
Norman
B H
BH
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Dantzig
A H
AH
Kroin
J S
JS
Law
K L
KL
Tabas
L B
LB
Shepard
R L
RL
Palkowitz
A D
AD
Hauser
K L
KL
Winter
M A
MA
Sluka
J P
JP
Starling
J J
JJ
D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors*; D000970:Antineoplastic Agents / Q000494:pharmacology; D001692:Biological Transport; D002462:Cell Membrane / Q000378:metabolism; D018432:Drug Resistance, Multiple / Q000235:genetics*; D018922:HL-60 Cells; D006367:HeLa Cells; D006801:Humans; D017997:Leukotriene C4 / Q000037:antagonists & inhibitors / Q000378:metabolism; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D013449:Sulfonamides / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology*
D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D017997:Leukotriene C4; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D013449:Sulfonamides; D013876:Thiophenes; C402711:LY 329146